A Study of Second- and Later-line Palliative Chemotherapy in Patients With Metastatic Colorectal Cancer.

Sponsor
Boryung Pharmaceutical Co., Ltd
Study ID
NCT07263178
Status
Recruiting
Apply to this trial

Conditions

  • Metastatic Colorectal Cancer

Eligibility Criteria

Sex
ALL
Age
19 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Second and later-line palliative chemotherapy — DRUG
    As this is a non-interventional study designed to collect data as part of routine clinical practice, the selection and dosage of medication, treatment period, and whether or not to change it are all based on the clinician's judgment

Study Details

This study aims to comprehensively identify the various treatment patterns of second- or subsequent-line palliative chemotherapy used in patients with metastatic colorectal cancer who have experienced failure of first-line palliative chemotherapy and to evaluate the prognosis of each treatment.

Key Dates

First listed
Dec 4, 2025
Start date
Nov 7, 2025
Status verified
Nov 2025
Primary completion
Dec 31, 2029
Completion
Dec 31, 2029

Study Design

Enrollment
1,000 participants (estimated)

Primary Outcome Measure

Progression-free survival (PFS) [ Time Frame: up to 24 months ]

Central Contacts

Related Studies